Protalix BioTherapeutics (NYSE:PLX – Get Free Report) and BioCardia (NASDAQ:BCDA – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.
Valuation and Earnings
This table compares Protalix BioTherapeutics and BioCardia”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Protalix BioTherapeutics | $65.49 million | 2.02 | $8.31 million | ($0.13) | -13.85 |
| BioCardia | $71,000.00 | 134.29 | -$11.57 million | ($4.19) | -0.50 |
Protalix BioTherapeutics has higher revenue and earnings than BioCardia. Protalix BioTherapeutics is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Protalix BioTherapeutics | -21.03% | -30.89% | -11.74% |
| BioCardia | -1,999.77% | N/A | -208.38% |
Institutional and Insider Ownership
16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 20.6% of BioCardia shares are owned by institutional investors. 6.3% of Protalix BioTherapeutics shares are owned by company insiders. Comparatively, 20.0% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Protalix BioTherapeutics and BioCardia, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Protalix BioTherapeutics | 0 | 0 | 0 | 0 | 0.00 |
| BioCardia | 0 | 0 | 1 | 0 | 3.00 |
BioCardia has a consensus price target of $25.00, indicating a potential upside of 1,101.92%. Given BioCardia’s stronger consensus rating and higher probable upside, analysts plainly believe BioCardia is more favorable than Protalix BioTherapeutics.
Volatility & Risk
Protalix BioTherapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, BioCardia has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.
Summary
BioCardia beats Protalix BioTherapeutics on 9 of the 14 factors compared between the two stocks.
About Protalix BioTherapeutics
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
About BioCardia
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
Receive News & Ratings for Protalix BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
